Gepants for headache prevention in children and adolescents: A multicenter chart review study.
Lauren Shin, Olivia Mentz, Amy A Gelfand...
https://pubmed.ncbi.nlm.nih.gov/41235617/Actively Recruiting
Led by Pfizer · Updated on 2026-10-14
640
Participants Needed
93
Research Sites
187 weeks
Total Duration
Researchers are evaluating the efficacy and safety of rimegepant compared to a placebo as a preventative treatment for children and adolescents aged 6 to under 18 years with episodic migraine. The study focuses on reducing the number of migraine days per month and improving quality of life in this young population. It is a Phase 3, randomized, double-blind, placebo-controlled trial sponsored by Pfizer. Participants receive either rimegepant in doses of 75mg or 50mg two 25mg orally disintegrating tablets or a matching placebo with the same dosing options. The study uses a double-blind design over a 12-week treatment phase to compare outcomes. The research also monitors safety and tolerability for up to 72 weeks, including the frequency of liver-related adverse events. During the study, participants will have assessments to record migraine days and severity, use of acute migraine medications, and quality of life using the Pediatric Quality of Life Inventory. Researchers will track safety through ongoing monitoring for adverse effects. The primary measure is the change in mean monthly migraine days over 12 weeks, with additional evaluations during the first 4 weeks and longer-term safety follow-up. Total participation may last up to 72 weeks for safety evaluation.
CONDITIONS
Efficacy and Safety Study of Rimegepant for the Preventative Treatment of Migraine in Pediatric Subjects
P
Pfizer Pfizer CT.gov Call Center
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Pfizer
Lead Sponsor
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
| Factors | Rimegepant (ODT) | Placebo | Current guideline-supported prevention |
|---|---|---|---|
| What it is | An investigational oral disintegrating tablet formulation of rimegepant given daily at either 75 mg or 50 mg (2 × 25 mg) for migraine prevention in children and adolescents. | A matched placebo tablet given under the same regimen as rimegepant. | Preventive medications such as propranolol or topiramate have been historically used off‑label in pediatric migraine according to clinical guidelines. |
| Role in trial | Investigational preventive treatment being evaluated for efficacy and safety versus placebo. | Serving as the control arm for comparison. | Represents current off‑label preventive options used in clinical practice. |
| Primary use | Prevention of migraine attacks in pediatric patients. | Inactive control for trial comparison. | Prevention of migraine as recommended in pediatric migraine care guidelines. |
| How it is given or performed | Administered orally as an orally disintegrating tablet once daily. | Administered orally as a matching orally disintegrating tablet once daily. | Typically oral daily dosing, e.g. propranolol or topiramate as used in pediatrics. |
| Evidence status | Evidence being collected in randomized pediatric trial; no results posted yet. | Control for evaluating investigational treatment; no direct efficacy evidence. | Some evidence suggests propranolol may reduce headache frequency and topiramate may decrease headache days compared with placebo. |
| Important risks | Safety and tolerability are being evaluated over long‑term follow‑up (up to 72 weeks) including monitoring for hepatic‑related adverse events. | Placebo control with similar monitoring schedule but without active drug risk. | Propranolol and topiramate have known side effects including fatigue, mood changes, and cognitive effects in some children. |
| Important limitations | No pediatric efficacy or safety results available yet since the trial is ongoing. | Placebo gives no clinical benefit and results have to be interpreted relative to an inert comparator. | Guideline‑recommended agents have limited evidence and trials often fail to show superiority over placebo. |
| Patient impact | Not yet established; trial is ongoing so impact on migraine burden or quality of life in children is unknown. | Not applicable; placebo offers no therapeutic benefit. | Some children may experience reduced headache frequency or days, but benefits are modest and evidence is limited. |
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - 12 weeks
Participants receive either rimegepant or a placebo tablet during the 12-week double-blind phase to prevent migraine.
Regular visits during treatment phase
Duration - Up to 72 weeks
Participants are monitored for safety and tolerability of the treatment for up to 72 weeks.
Periodic safety assessments
Study Type
INTERVENTIONAL
Masking
QUADRUPLE
Allocation
RANDOMIZED
Model
SEQUENTIAL
Primary Purpose
PREVENTION
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Lauren Shin, Olivia Mentz, Amy A Gelfand...
https://pubmed.ncbi.nlm.nih.gov/41235617/Pfizer
Lead Sponsor